LOG IN
SIGN UP
News
ABUS
--
0.00%
--
Is Arbutus Biopharma Corp (ABUS) A Good Stock To Buy?
Insider Monkey · 06/16 01:18
Arbutus to Present at Jefferies Virtual Healthcare Conference
WARMINSTER, Pa., May 27, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic.
GlobeNewswire · 05/27 12:00
61 Biggest Movers From Yesterday
Gainers Nano Dimension Ltd. (NASDAQ: NNDM) shares surged 341.7% to close at $3.40 on Tuesday. HENSOLDT and Nano Dimension achieved a major breakthrough in electronics 3D printing.
Benzinga · 05/20 08:50
Mid-Afternoon Market Update: NASDAQ Rises 70 Points; ShiftPixy Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.18% to 24552.63 while the NASDAQ rose 0.76% to 9304.91. The S&P also rose, gaining 0.21% to 2960.01.
Benzinga · 05/19 18:33
44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Nano Dimension Ltd. (NASDAQ: NNDM) jumped 85.8% to $1.43. HENSOLDT and Nano Dimension achieved a major breakthrough in electronics 3D printing.
Benzinga · 05/19 16:48
Mid-Day Market Update: Crude Oil Up 2%; Bellerophon Therapeutics Shares Plummet
Midway through trading Tuesday, the Dow traded down 0.11% to 24569.40 while the NASDAQ rose 0.73% to 9302.01. The S&P also rose, gaining 0.19% to 2959.67.
Benzinga · 05/19 16:23
UPDATE: Wedbush Upgrades Arbutus Biopharma To Outperform, Raises Target To $4 'following positive 12-Week 60 mg single-dose data for AB-729 in chronic HBV patients'
Benzinga · 05/19 16:14
P/E Ratio Insights for Arbutus Biopharma
Benzinga · 05/19 16:11
P/E Ratio Insights for Arbutus Biopharma
Benzinga · 05/19 15:11
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18)
Benzinga · 05/19 12:27
Wedbush Upgrades Arbutus Biopharma to Outperform, Raises Price Target of $4
Wedbush analyst Robert Driscoll upgrades Arbutus Biopharma (NASDAQ:ABUS) from Neutral to Outperform and raises the price target from $2 to $4.
Benzinga · 05/19 12:26
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Kirkland's, Inc. (NASDAQ: KIRK) shares rose 54.3% to $1.30 in pre-market trading after the company said e-commerce demand was up 96% in the period since stores closed on March 19th.
Benzinga · 05/19 11:20
82 Biggest Movers From Yesterday
Gainers cbdMD, Inc. (NASDAQ: YCBD) rose 81.4% to close at $1.76 following strong Q2 earnings.
Benzinga · 05/19 08:44
Arbutus up 46% after hours on positive data on HBV candidate
Arbutus Biopharma (NASDAQ:ABUS) announces positive follow-up data from a Phase 1a/1b clinical trial evaluating a single 60 mg subcutaneous injection of RNA
seekingalpha · 05/19 02:03
Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg
GlobeNewswire · 05/18 21:05
6 Stocks Moving In Monday's After-Hours Session
Gainers Kirkland's (NASDAQ: KIRK) shares are trading higher after the company said e-commerce demand was up 96% in the period since stores closed on March 19.
Benzinga · 05/18 20:54
Arbutus Highlights Single-Dose Week 12 Data In Chronic Hep B Subjects With 60 mg AB-729 Showed 'Significant, Continuous Reduction In HBsAg'
Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today reports positive follow-up data from a
Benzinga · 05/18 20:07
Forecast: Analysts Think Arbutus Biopharma Corporation's (NASDAQ:ABUS) Business Prospects Have Improved Drastically
Simply Wall St. · 05/18 11:05
Why Arbutus (ABUS) Stock Might be a Great Pick
Zacks · 05/15 16:04
Arbutus' Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Arbutus Biopharma.
Zacks · 05/15 13:15